Showing 141-150 of 3976 results for "".
Dr. Joel Schlessinger discusses Botox treatments
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-joel-schlessinger-discusses-botox-treatments/19321/Joel Schlessinger, MD takes you through a BOTOX treatment step-by-step, explaining each piece of the process. The video begins with a quick description of BOTOX, Dysport and Xeomin before moving on to show the process of taking pre-treatment photos and performing a consultation. Dr. Schlessinger thePhase 2 and 3 Trials of JAK Inhibitors For Atopic Dermatitis: A Review
https://practicaldermatology.com/topics/atopic-dermatitis/phase-2-and-3-trials-of-jak-inhibitors-for-atopic-dermatitis-a-review/23265/A number of drugs in development show promise for one of the most challening skin diseases.Patient-Centered Wound Healing
https://practicaldermatology.com/topics/feature/patient-centered-wound-healing/26645/Patient-Centered Wound HealingJAK Inhibitors in Hidradenitis Suppurativa: A Systematic Review
https://practicaldermatology.com/topics/feature/jak-inhibitors-in-hidradenitis-suppurativa-a-systematic-review/29887/Hidradenitis suppurativa (HS) is a chronic, disfiguring, debilitating, inflammatory disorder that is characterized by inflammatory nodules, abscesses, fistulae/ sinus tracts, and scarring to the axilla, inframammary folds, and groin.Home-Use Laser and Light Devices: Just What the Doctor Ordered
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/home-use-laser-and-light-devices-just-what-the-doctor-ordered/23335/Laser and light-based devices are more at home than ever as lightweight LEDs, wearable technology, and “smart” apps support adherence and enhance efficacy.Vitiligo: Oral and Topical JAKs Show Promise
https://practicaldermatology.com/topics/pigmentary-disorders/vitiligo-oral-and-topical-jaks-show-promise/23316/Early studies offer some hope for emerging therapies for repigmentation.Bimekizumab-bkzx Journal Scan: 4 Clinical Trials
https://practicaldermatology.com/topics/digital-supplement/bimekizumab-bkzx-journal-scan-4-clinical-trials/24128/Speed, depth, and durability from the first dual IL-17A/F inhibitor for the treatment of moderate to severe plaque psoriasis.Technology Solutions: Q&A With Nextech's Dr. Jason Handza
https://practicaldermatology.com/topics/practice-management/technology-solutions-q-nextechs-dr-jason-handza/28649/Nextech this year introduced Nextech RCM Professional Billing Services, an addition to their practice management software suite. This solution simplifies insurance billing complexities, helping practices reduce administrative burdens and enhance financial performance through optimized cash flow.The Excoriated and Bleeding Edge: Updates in Eczema for the Clinician
https://practicaldermatology.com/topics/general-topics/the-excoriated-and-bleeding-edge-updates-in-eczema-for-the-clinician/21469/Atopic dermatitis continues to present treatment challenges, but a steady juggling of four main components—moisturization, antibiotics, anti-inflammatory, and antipruritics— help to maximize control of the disease.Lose Your Inhibitions: Expanding Use of JAK Inhibitors
https://practicaldermatology.com/topics/atopic-dermatitis/lose-your-inhibitions-expanding-use-of-jak-inhibitors/23910/Despite data on safety concerns, dermatologists and patients see benefits.